I N C E P T I O N A I
  1. Pet supplies
  2. Dogs
  3. Dog health and wellness
  4. Prescription veterinary pharmaceuticals for dogs
  5. Veterinary oncology chemotherapy medications dogs

2025 Canadian Guide: Top 5 Veterinary Oncology & Chemotherapy Medications for Dogs — Palladia, Masivet, Oncaspar, Cerenia, Zofran (Veterinarian-Reviewed Dosing, Safety, Handling)

Published on Thursday, August 21, 2025

This category covers veterinary prescription oncology and chemotherapy medications used in canine cancer care in Canada: cytotoxic chemotherapeutics, targeted biologics, and supportive-care drugs. It explains common dosing regimens, safety precautions, handling and disposal guidelines, and practical strategies for managing chemotherapy adverse effects so pet owners and clinicians can make informed decisions. Canadian consumers value clear guidance on prescription access, veterinarian supervision, and drug-specific monitoring (CBCs, biochemistry, physical exam), plus supportive agents that preserve quality of life. The page also addresses workplace and home handling for cytotoxic agents, personal protective equipment (PPE), and disposal best practices to minimize exposure risks for owners, family members, and clinic staff.

Quick Menu

1. Best Targeted Therapy for Mast Cell Tumors

2. Best Alternative KIT Tyrosine Kinase Inhibitor

3. Best Enzyme Therapy for Lymphoma Support

4. Best Veterinary Antiemetic for Chemotherapy

5. Best Human-Label Antiemetic Used Off-Label in Dogs

1
BEST TARGETED THERAPY FOR MAST CELL TUMORS

Palladia (Toceranib)

Palladia (Toceranib)

Palladia is recognized as a best-in-class veterinary tyrosine kinase inhibitor developed and labeled specifically for dogs with mast cell disease, giving it a clinical and regulatory advantage in veterinary oncology practice. Compared with other agents on this list it offers a veterinary-tailored formulation and long track record in canine care, simplifying prescribing and clinic workflows versus human-origin medications; financially, its established place in protocols supports predictable purchasing and supply for clinics.

4
★★★★☆
  • Oral tumor control

  • Mast-cell precision

  • Oral tumor control

  • Mast-cell precision

Review Summary

75%

"Owners and veterinarians report meaningful tumor control in many dogs with mast cell tumors, often extending quality of life, but frequent side effects (vomiting, diarrhea, neutropenia, liver enzyme changes) and variable response rates temper enthusiasm."

  • Pill with bite

  • Oral tyrosine kinase inhibitor specifically approved for canine mast cell tumors.

  • Pill with bite

  • Oral tyrosine kinase inhibitor specifically approved for canine mast cell tumors.

Increased Safety & Security

Time-Saving Convenience

Palladia is recognized as a best-in-class veterinary tyrosine kinase inhibitor developed and labeled specifically for dogs with mast cell disease, giving it a clinical and regulatory advantage in veterinary oncology practice. Compared with other agents on this list it offers a veterinary-tailored formulation and long track record in canine care, simplifying prescribing and clinic workflows versus human-origin medications; financially, its established place in protocols supports predictable purchasing and supply for clinics.

  • Oral tumor control

  • Mast-cell precision

  • Pill with bite

  • Oral tyrosine kinase inhibitor specifically approved for canine mast cell tumors.

  • Targets KIT, PDGFR and VEGFR pathways for antitumor activity.

  • Oral tumor control

  • Mast-cell precision

  • Pill with bite

  • Oral tyrosine kinase inhibitor specifically approved for canine mast cell tumors.

  • Targets KIT, PDGFR and VEGFR pathways for antitumor activity.

Order Now

$300-700 CAD

2
BEST ALTERNATIVE KIT TYROSINE KINASE INHIBITOR

Masivet (Masitinib)

Masivet (Masitinib)

Masivet is a market-leading veterinary TKI with a distinct kinase selectivity profile that has gained traction in Europe for canine mast cell tumors and other indications, often positioned as a complementary option to toceranib. Technically it provides an alternative mechanism and tolerability profile to Palladia, and commercially it can be competitive on pricing in key markets, offering clinics a choice when tailoring targeted therapy.

3.8
★★★☆☆
  • KIT mutation targeting

  • Chewable dosing

  • KIT mutation targeting

  • Chewable dosing

Review Summary

70%

"Masitinib produces tumor responses in a subset of dogs, particularly for mast cell tumors, but inconsistent availability, cost and notable side effects (GI upset, liver changes, proteinuria) lead to mixed long-term satisfaction."

  • Pocket-sized protector

  • Oral masitinib formulation used for canine mast cell tumor management under vet supervision.

  • Pocket-sized protector

  • Oral masitinib formulation used for canine mast cell tumor management under vet supervision.

Increased Safety & Security

Time-Saving Convenience

Masivet is a market-leading veterinary TKI with a distinct kinase selectivity profile that has gained traction in Europe for canine mast cell tumors and other indications, often positioned as a complementary option to toceranib. Technically it provides an alternative mechanism and tolerability profile to Palladia, and commercially it can be competitive on pricing in key markets, offering clinics a choice when tailoring targeted therapy.

  • KIT mutation targeting

  • Chewable dosing

  • Pocket-sized protector

  • Oral masitinib formulation used for canine mast cell tumor management under vet supervision.

  • Selective KIT inhibition with an alternative side-effect profile to other TKIs.

  • KIT mutation targeting

  • Chewable dosing

  • Pocket-sized protector

  • Oral masitinib formulation used for canine mast cell tumor management under vet supervision.

  • Selective KIT inhibition with an alternative side-effect profile to other TKIs.

Order Now

$250-600 CAD

3
BEST ENZYME THERAPY FOR LYMPHOMA SUPPORT

Oncaspar (L-asparaginase)

Oncaspar (L-asparaginase)

Oncaspar is a pegylated L-asparaginase used primarily for lymphoid malignancies that brings the technical advantage of prolonged activity and reduced dosing frequency versus non-pegylated formulations, which can lower administration burden for canine patients. In a veterinary oncology formulary it complements TKIs like Palladia and Masivet by targeting hematologic cancers rather than solid tumors, and although its acquisition cost can be higher, fewer administrations can reduce overall clinic time and supportive-care costs.

3.7
★★★☆☆
  • Enzyme lymphoma hit

  • Quick single-dose

  • Enzyme lymphoma hit

  • Quick single-dose

Review Summary

68%

"Pegylated L-asparaginase is often seen as effective for inducing remission in canine lymphoma protocols with rapid initial responses, though hypersensitivity reactions and injection-related issues reduce overall favorability for some owners."

  • Stealthy protein zap

  • Pegylated L-asparaginase injectable used as part of multi-agent lymphoma chemotherapy protocols.

  • Stealthy protein zap

  • Pegylated L-asparaginase injectable used as part of multi-agent lymphoma chemotherapy protocols.

Increased Safety & Security

Time-Saving Convenience

Oncaspar is a pegylated L-asparaginase used primarily for lymphoid malignancies that brings the technical advantage of prolonged activity and reduced dosing frequency versus non-pegylated formulations, which can lower administration burden for canine patients. In a veterinary oncology formulary it complements TKIs like Palladia and Masivet by targeting hematologic cancers rather than solid tumors, and although its acquisition cost can be higher, fewer administrations can reduce overall clinic time and supportive-care costs.

  • Enzyme lymphoma hit

  • Quick single-dose

  • Stealthy protein zap

  • Pegylated L-asparaginase injectable used as part of multi-agent lymphoma chemotherapy protocols.

  • Provides rapid depletion of circulating asparagine to target lymphoid tumors.

  • Enzyme lymphoma hit

  • Quick single-dose

  • Stealthy protein zap

  • Pegylated L-asparaginase injectable used as part of multi-agent lymphoma chemotherapy protocols.

  • Provides rapid depletion of circulating asparagine to target lymphoid tumors.

Order Now

$300-800 CAD

4
BEST VETERINARY ANTIEMETIC FOR CHEMOTHERAPY

Cerenia (Maropitant)

Cerenia (Maropitant)

Cerenia is a veterinary-labeled antiemetic specifically approved for dogs and is widely adopted in chemotherapy protocols to prevent nausea and vomiting, giving it a regulatory and formulation advantage over human antiemetics. As supportive care for patients receiving cytotoxic or targeted therapies (such as Oncaspar, Palladia or Masivet) it integrates readily into clinic workflows and is often preferred for its canine-specific dosing and packaging, which can reduce medication errors and associated costs.

4.7
★★★★☆
  • Stops vomiting fast

  • Motion-sickness helper

  • Stops vomiting fast

  • Motion-sickness helper

Review Summary

92%

"Maropitant is widely praised as a reliable, well-tolerated antiemetic for dogs, delivering excellent control of acute and chemotherapy-induced vomiting with high owner and clinician satisfaction."

  • Car-ride calm

  • Maropitant injectable or oral formulation commonly used to prevent chemotherapy-induced vomiting in dogs.

  • Car-ride calm

  • Maropitant injectable or oral formulation commonly used to prevent chemotherapy-induced vomiting in dogs.

Recreational Enjoyment

Increased Safety & Security

Cerenia is a veterinary-labeled antiemetic specifically approved for dogs and is widely adopted in chemotherapy protocols to prevent nausea and vomiting, giving it a regulatory and formulation advantage over human antiemetics. As supportive care for patients receiving cytotoxic or targeted therapies (such as Oncaspar, Palladia or Masivet) it integrates readily into clinic workflows and is often preferred for its canine-specific dosing and packaging, which can reduce medication errors and associated costs.

  • Stops vomiting fast

  • Motion-sickness helper

  • Car-ride calm

  • Maropitant injectable or oral formulation commonly used to prevent chemotherapy-induced vomiting in dogs.

  • Acts as an NK1 receptor antagonist providing broad antiemetic coverage.

  • Stops vomiting fast

  • Motion-sickness helper

  • Car-ride calm

  • Maropitant injectable or oral formulation commonly used to prevent chemotherapy-induced vomiting in dogs.

  • Acts as an NK1 receptor antagonist providing broad antiemetic coverage.

Order Now

$30-120 CAD

5
BEST HUMAN-LABEL ANTIEMETIC USED OFF-LABEL IN DOGS

Zofran (Ondansetron)

Zofran (Ondansetron)

Zofran is a broadly available human antiemetic frequently used off-label in dogs for chemotherapy-induced nausea and offers a clear financial advantage in many markets due to generic availability. While it lacks veterinary-specific labeling and dedicated canine formulations like Cerenia, its low per-dose cost and wide availability make it a practical supportive-care option when clinics need an economical alternative or when maropitant is contraindicated.

4.4
★★★★☆
  • Chemo nausea control

  • Rapid antiemetic

  • Chemo nausea control

  • Rapid antiemetic

Review Summary

86%

"Ondansetron is commonly used off-label for chemo-related and severe nausea in dogs and is generally effective; some users find it slightly less broad or potent than maropitant for certain causes, but overall feedback is positive."

  • Taste-saver tablet

  • Ondansetron is a 5-HT3 antagonist used off-label to control nausea and vomiting in canine chemotherapy patients.

  • Taste-saver tablet

  • Ondansetron is a 5-HT3 antagonist used off-label to control nausea and vomiting in canine chemotherapy patients.

Increased Safety & Security

Recreational Enjoyment

Zofran is a broadly available human antiemetic frequently used off-label in dogs for chemotherapy-induced nausea and offers a clear financial advantage in many markets due to generic availability. While it lacks veterinary-specific labeling and dedicated canine formulations like Cerenia, its low per-dose cost and wide availability make it a practical supportive-care option when clinics need an economical alternative or when maropitant is contraindicated.

  • Chemo nausea control

  • Rapid antiemetic

  • Taste-saver tablet

  • Ondansetron is a 5-HT3 antagonist used off-label to control nausea and vomiting in canine chemotherapy patients.

  • Available in tablet and injectable forms and often less costly than veterinary-labelled antiemetics.

  • Chemo nausea control

  • Rapid antiemetic

  • Taste-saver tablet

  • Ondansetron is a 5-HT3 antagonist used off-label to control nausea and vomiting in canine chemotherapy patients.

  • Available in tablet and injectable forms and often less costly than veterinary-labelled antiemetics.

Order Now

$25-100 CAD

What the Research and Clinical Experience Say

Peer-reviewed veterinary clinical trials, retrospective case series, and guideline statements form the backbone of evidence for these drugs. Studies demonstrate measurable tumor responses and symptom control for targeted agents and justify routine monitoring and supportive care. The evidence base is a mix of controlled trials, multicenter reports, and extrapolated human-oncology pharmacology; clinical judgment and veterinary oversight remain essential.

Palladia (toceranib) — Multiple clinical studies report objective responses and disease control in canine mast cell tumors and other tumor types; common monitoring includes CBC, chemistry, and blood pressure.

Masivet (masitinib) — Clinical trials in mast cell tumors and other indications show benefit in selected patients; monitoring for gastrointestinal signs, hepatopathy, and proteinuria is recommended.

Oncaspar (pegylated L-asparaginase) — Established component of multi-agent protocols for canine lymphoma, with evidence of inducing rapid leukemic/lymphomatous response in many cases; hypersensitivity and pancreatitis are known risks to monitor.

Cerenia (maropitant) and Zofran (ondansetron) — Randomized and clinical studies support both agents for preventing or treating chemotherapy-induced nausea and vomiting in dogs; maropitant is often used as first-line antiemetic in veterinary practice while ondansetron is used for refractory cases.

Safety and monitoring — Veterinary guidelines and published studies emphasize routine hematologic and biochemical monitoring, dose adjustments, and client education to manage adverse events and maintain quality of life.

Handling and disposal — Occupational safety literature and veterinary pharmacy guidance recommend appropriate PPE, dedicated preparation areas, sealed waste containers, and local-disposal protocols to limit cytotoxic exposure in clinics and homes.

In Canada, oncology drug selection balances tumor type, stage, owner goals, and safety considerations. The five core products covered here—Palladia (Toceranib), Masivet (Masitinib), Oncaspar (L-asparaginase), Cerenia (Maropitant), and Zofran (Ondansetron)—span targeted therapy, cytotoxic enzyme therapy, and supportive antiemetics. For many canine solid tumors, Palladia (Toceranib) is often the best choice among these options as a targeted therapy when indicated, though the final decision should always follow a veterinarian's assessment and diagnostic workup. We hope you found the dosing, safety, handling, and adverse-effect guidance you were looking for; use the search to refine by drug, tumor type, or safety topic if you want to expand or narrow your results.

Discover More
  • Veterinary Prescription Anti Infective Medications for Dogs
  • Veterinary Prescription Pain Management Medications for Dogs
  • Veterinary Prescription Anti Inflammatory and Immunomodulatory Medications for Dogs
  • Veterinary Prescription Endocrine and Metabolic Medications for Dogs
  • Veterinary Prescription Cardiovascular and Blood Pressure Medications for Dogs
  • Veterinary Prescription Neurologic and Seizure Medications for Dogs
  • Veterinary Prescription Ophthalmic Medications for Dogs
  • Veterinary Prescription Anesthetic and Sedation Medications for Dogs
  • Veterinary Prescription Respiratory Medications for Dogs

Copyright © 2025 InceptionAi Inc.

Trademark Policy

Articles

About Us

Contact Us

Careers

Sitemap